Based on our previous clinical data regarding the major role of CD4+ T cells in T1D [12,14], the purified CD4+ T cells were focused and treated by platelet-derived mitochondria to further explore the molecular mechanisms underlying SCE therapy for the treatment of T1D. The gene discussed is CD4; the disease is type 1 diabetes mellitus.